Angelini Pharma
About Angelini Pharma
Angelini Pharma is an international pharmaceutical company focused on Brain Health, including Mental Health and Epilepsy, as well as other therapeutic areas such as pain, oncology, consumer health, and rare diseases. The company conducts research, development and commercialization across its global operations, with an emphasis on CNS, infectious diseases, and consumer healthcare. Its presence spans multiple European countries and the United States, reflecting a broad portfolio of brands and ongoing collaborations, trials, and sustainability initiatives. Angelini is part of the Angelini Industries group and maintains offices and activities worldwide, including Europe, the UK, and the USA.
Recent News
Makary Resigns, BMS Bets $15B on China R&D, and Regenxbio Wins Phase 3 in Duchenne – This Week in Biotech #100
Pharma and Biotech M&As 2026 Deal Watcher
InsideArbitrage Event Driven Monitor – May 29, 2026
InsideArbitrage Event Driven Monitor – May 8, 2026
Italy’s Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion
Pharmaceutical Executive Daily: Angelini Pharma Acquires Catalyst Pharmaceuticals in $4.1 Billion Agreement
Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion